Marion A. Kainer, MD, MPH, FRACP, FSHEA, Director of Healthcare Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, warns of the dangers of the most underrated healthcare associated infections, and explains how best to treat them.
Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, discusses key points to consider when deciding what drug dosage to prescribe to a patient.
Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, President, Society of Infectious Diseases Pharmacists, shares what is known about the Pennsylvania superbug case and whether or not others can be infected.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, discusses the prognosis for babies born with Zika-linked microcephaly.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, discusses the medical condition of the tri-state area's first Zika-linked microcephaly baby.
Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, explains how changes in antimicrobial resistance should be reflected in drug dosage.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, discusses the diagnosis and delivery of the tri-state area’s first Zika-infected microcephaly baby.
Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, discusses the importance of healthcare providers knowing the differences between pharmacokinetics and pharmacodynamics.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, discusses the length of time during which a mother can pass on a Zika infection to her fetus with Contagion.
Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, President, Society of Infectious Diseases Pharmacists, shares his thoughts on the “elephant in the room” with regards to antimicrobial stewardship.
Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, outlines the differences between Pharmacokinetics and Pharmacodynamics.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, explains whether or not someone can contract the Zika virus from an infected baby.
Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, president, Society of Infectious Diseases Pharmacists, explains what healthcare providers need to know about this most recent case of a superbug infection in the US.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, explains the threat of Zika, and when it is most harmful to a fetus.
Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, explains the difference between Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus.
Abdulla Al-Khan, MD, director of the Division of Maternal-Fetal Medicine and Surgery at Hackensack University Medical Center, describes the diagnosis of the tri-state area's first case of Zika-linked microcephaly in a newborn child.
Justin R. Anderson, PhD, associate professor of biology at Radford University, describes his research on the effects of endocrine disrupting chemicals on mosquito-borne viruses.
Kirk Hevener, PharmD, PhD, explains the importance of narrow-spectrum antibacterial targets.
Romney Humphries, PhD, D(ABMM), discusses new technologies to detect antimicrobial susceptibility and resistance that are currently under production.
Craig Rubens, MD, PhD, co-founder and executive director of GAPPS at Seattle Children’s Hospital, describes the current disease burden of neonatal infections across the globe.
Andrew Chasteen from Accelerate Diagnostics, Inc, explains Morphokinetic Cellular Analysis (MCA) and how it differs from other analyses.
Prof. Andrea Endimiani, MD, PhD, from the Institute of Infectious Diseases at the University of Bern, Switzerland, explains which pathogens are most affected by the colistin resistant mcr-1 gene.
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, explains the current state of the antimicrobial pipeline.
Monica Mahoney, PharmD, BCPS-AQ ID, clinical pharmacy coordinator of infectious diseases at Beth Israel Deaconess Medical Center, explains the antimicrobial considerations that are specific to the solid organ transplant population.
Emily Heil, PharmD, BCPS-AQ ID, from the University of Maryland School of Pharmacy, discusses the concerns of antibiotic use in agriculture.
Jason C. Gallagher, PharmD, president, Society of Infectious Diseases Pharmacists, explains if we know how the case of mcr-1 E. coli superbug was contracted.
Marion A. Kainer, MD, MPH, FRACP, FSHEA, Director of Healthcare Associated Infection and Antimicrobial Resistance Program, Tennessee Department of Health, discusses some of the key points to aid in the fight against healthcare associated infections, nationwide.
Jason C. Gallagher, PharmD, President, Society of Infectious Diseases Pharmacists describes the recent case of an antibiotic resistant “superbug” in Pennsylvania.
Marion A. Kainer, MD, MPH, FRACP, FSHEA, Director, Healthcare Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, explains how the CDC aid state health departments in the fight against healthcare associated infections.
Christina G. Tan, MD, MPH, FACP, New Jersey State Epidemiologist/Assistant Commissioner, outlines New Jersey Department of Health’s role in vaccine awareness.
